A multisociety Delphi consensus statement on new fatty liver disease nomenclature

★

☆

SHARE

Overview

Paper Summary

Conflicts of Interest

Identified Weaknesses

Rating Explanation

Good to know

Topic Hierarchy

File Information

Paper Summary

Paperzilla title

From NAFLD to MASLD: A New Name for Fatty Liver Disease

The study proposes replacing "NAFLD" with "MASLD" (metabolic dysfunction-associated steatotic liver disease), reflecting the central role of metabolic dysfunction. It also proposes diagnostic criteria based on the presence of at least one cardiometabolic risk factor and creates a separate category ("MetALD") for patients with MASLD and increased alcohol consumption.

Possible Conflicts of Interest

Many authors disclosed consulting relationships with or receiving grants from pharmaceutical companies involved in NAFLD research and treatment.

Identified Weaknesses

Potential bias in the Delphi panel

The Delphi method, while useful for gathering expert opinions, can be susceptible to bias and may not fully capture the diversity of perspectives on a complex issue like NAFLD nomenclature.

Rating Explanation

This study used a robust, multi-stage Delphi process with a diverse panel of experts and patient advocates to reach consensus on new nomenclature for fatty liver disease. The thorough methodology, global representation, and inclusion of patient perspectives are strengths. However, potential bias in the Delphi method and the declared COIs of some authors slightly lower the rating.

Good to know

This is our free standard analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.

Explore Pro →